Cancer biomarkers are biological molecules that are produced by tumour cells or by human tissues in response to cancer. These molecules are then measured and assessed as a sign of cancerous processes occurring within the body. Cancer biomarkers are widely used in the diagnosis and treatment of cancer patients. Biomarkers are used in follow-up surveillance and for the early detection of potential recurrent disease in cancer patients who have had curative surgery. Molecular biomarkers are also used as part of standard diagnostic procedures as part of ongoing advancements in cancer diagnosis.
The global Cancer Biomarkers Market is expected to be worth US$ 21,643.9 million in 2022, with a CAGR of 14.4% during the forecast period (2022-2030).
Leading Companies in the Cancer Biomarkers Industry:
1. bioMérieux, Inc.
The headquarters of the French multinational biotechnology company bioMérieux SA are in Marcy-l'Étoile, close to Lyon. bioMérieux has a presence in 44 countries and serves over 160 countries via a large network of distributors.
bioMerieux, Inc. Announces New Results from Their Breast Cancer Blood Biomarkers Program.
2. INOVIQ
INOVIQ Ltd is developing and commercialising an innovative portfolio of diagnostic and exosome-based products to improve cancer and other disease diagnosis and treatment. The company has commercialised the hTERT test, which is used as an adjunct to urine cytology testing for bladder cancer, as well as the EXO-NET pan-exosome capture tool, which is used for research. Blood tests for earlier detection and monitoring of ovarian, breast, prostate, and other cancers are in development in our cancer diagnostic pipeline.
SPR for cancer detection are pleased to announce our collaboration with INOVIQ.
3. Bio-Rad Laboratories, Inc.
Bio-Rad Laboratories, Inc. is a company based in the United States that develops and manufactures specialised technological products for the life science research and clinical diagnostics markets.
Bio-Rad offers solutions to key challenges in biomarker discovery and validation, including throughput, reliability, sensitivity, and usability. In addition to solutions for analysing genomic, proteomic, and cellular biomarkers.
